Wirth M, Manseck A, Heimbach D
Klinik und Poliklinik für Urologie, Medizinische Akademie Dresden, FRG.
Eur Urol. 1993;24 Suppl 2:6-12. doi: 10.1159/000474380.
Prostate-specific antigen (PSA) is the most important tumor marker for prostate cancer. However, the diagnostic limits of PSA have to be taken into consideration because PSA is also secreted by normal prostate tissue and, with benign prostatic hyperplasia, false positives are possible. Although there is a direct correlation between the serum PSA concentration and the clinical stage of the tumor, PSA is not sufficiently reliable to determine the stage of the disease on an individual basis. Low serum PSA concentrations (less than 20 ng/ml) in patients with previously untreated prostate cancer seem to be predictive for a negative bone scan. Serum PSA values also reflect the prognosis of the patient. With respect to monitoring patients after definitive therapy, PSA is a very sensitive tumor marker. However, in a small number of patients PSA-negative tumor recurrences occur.
前列腺特异性抗原（PSA）是前列腺癌最重要的肿瘤标志物。然而，必须考虑PSA的诊断局限性，因为正常前列腺组织也会分泌PSA，而且在良性前列腺增生的情况下，可能会出现假阳性。虽然血清PSA浓度与肿瘤临床分期之间存在直接关联，但PSA在个体基础上确定疾病分期的可靠性不足。既往未经治疗的前列腺癌患者血清PSA浓度较低（低于20 ng/ml）似乎提示骨扫描结果为阴性。血清PSA值也反映患者的预后。在确定性治疗后监测患者方面，PSA是一种非常敏感的肿瘤标志物。然而，少数患者会出现PSA阴性的肿瘤复发。
